Prestige BioPharma Limited (KRX:950210)
South Korea
· Delayed Price · Currency is KRW
13,320
+600 (4.72%)
At close: Mar 28, 2025, 3:30 PM KST
Prestige BioPharma Ratios and Metrics
Market cap in millions KRW. Fiscal year is July - June.
Millions KRW. Fiscal year is Jul - Jun.
| Current | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| Mar '25 Mar 31, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 | Jun '20 Jun 30, 2020 |
| Market Capitalization | 160,096 | 103,966 | 113,582 | 137,620 | 396,635 | - |
| Market Cap Growth | 59.39% | -8.47% | -17.47% | -65.30% | - | - |
| Enterprise Value | 195,234 | 44,042 | -6,736 | -150,494 | -63,944 | - |
| Last Close Price | 13320.00 | 8650.00 | 9450.00 | 11450.00 | 33000.00 | - |
| PE Ratio | - | - | 6.47 | - | - | - |
| Forward PE | - | 12.01 | 12.01 | 12.01 | - | - |
| PS Ratio | 136.46 | 150.88 | 701.81 | - | - | - |
| PB Ratio | 2.02 | 0.20 | 0.21 | 0.32 | 0.69 | - |
| P/TBV Ratio | 0.53 | 0.26 | 0.28 | 0.32 | 0.69 | - |
| EV/Sales Ratio | 33.26 | 63.92 | - | - | - | - |
| Debt / Equity Ratio | 0.36 | 0.20 | 0.21 | 0.01 | 0.01 | 0.02 |
| Debt / EBITDA Ratio | - | - | 9.11 | - | - | - |
| Asset Turnover | 0.01 | 0.00 | 0 | - | - | - |
| Inventory Turnover | 0.09 | 0.10 | 0.01 | - | - | - |
| Quick Ratio | 1.35 | 1.57 | 2.24 | 7.26 | 32.70 | 5.71 |
| Current Ratio | 1.47 | 1.72 | 2.31 | 7.46 | 32.74 | 5.88 |
| Return on Equity (ROE) | -11.71% | -10.38% | -0.59% | -42.08% | -2.07% | - |
| Return on Assets (ROA) | -5.41% | -5.35% | 0.10% | -13.89% | -3.01% | - |
| Return on Capital (ROIC) | -6.11% | -6.07% | 0.12% | -15.08% | -3.18% | - |
| Return on Capital Employed (ROCE) | - | - | 0.20% | - | - | - |
| Earnings Yield | -18.65% | -31.66% | 15.47% | -153.65% | -1.86% | - |
| FCF Yield | -56.84% | -65.49% | -95.65% | -74.36% | -4.13% | - |
| Buyback Yield / Dilution | 0.12% | - | - | -16.46% | -20.98% | - |
Source: S&P Global Market Intelligence. Standard template.
Financial Sources.